<p>Shanghai Henlius Biotech Inc. announced that the investigational new drug (IND) application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer, has been approved by the National Medical Products Administration. As of the date of the announcement, no SIRPα-Fc fusion protein targeting CD47 has been approved for marketing globally. The company noted that successful development and commercialization of HLX701 cannot be guaranteed and advised shareholders and potential investors to exercise caution. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260120-11995821), on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

512290

02696

516820

Reuters

Guotai CSI Bio-medicine ETF

HENLIUS

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Research Sector 100 ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application